Exact Mass: 552.302
Exact Mass Matches: 552.302
Found 500 metabolites which its exact mass value is equals to given mass value 552.302
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Bipindogulomethyloside
Bipindogulomethyloside is isolated from Convallaria majalis. Convallaria majalis is banned by the FDA from food use in the US Isolated from Convallaria majalis. Convallaria majalis is banned by the FDA from food use in the USA.
Pandamine
Handelin
Handelin is a sesterterpenoid. [(1R,2R,3R,3aR,4S,5S,6R,6aR,9S,9aR,9bR,10S,11R)-2,6-dihydroxy-2,6,9,11-tetramethyl-6-methylidene-2,7-dioxospiro[4,5,6a,7,9a,9b-hexahydro-3aH-azuleno[4,5-b]furan-3,15-8-oxatetracyclo[9.2.2.01,10.05,9]pentadec-12-ene]-4-yl] acetate is a natural product found in Tanacetum vulgare, Chrysanthemum lavandulifolium, and other organisms with data available. Handelin is a guaianolide dimer from Chrysanthemum boreale that has potent anti-inflammatory activity by down-regulating NF-κB signaling and pro-inflammatory cytokine production[1]. Handelin is a guaianolide dimer from Chrysanthemum boreale that has potent anti-inflammatory activity by down-regulating NF-κB signaling and pro-inflammatory cytokine production[1].
Triterpenoid
Triterpenoid is a byproduct from squalene 2,3-oxide decomposition. Squalene is a precursor to sterol biosynthesis. Terpenes are derived biosynthetically from units of isoprene, which has the molecular formula C5H8. The basic molecular formulas of terpenes are multiples of that, (C5H8)n where n is the number of linked isoprene units. This is called the isoprene rule or the C5 rule. The isoprene units may be linked together "head to tail" to form linear chains or they may can be arranged to form rings. One can consider the isoprene unit as one of natures preferred building blocks. [HMDB] Triterpenoid is a byproduct from squalene 2,3-oxide decomposition. Squalene is a precursor to sterol biosynthesis. Terpenes are derived biosynthetically from units of isoprene, which has the molecular formula C5H8. The basic molecular formulas of terpenes are multiples of that, (C5H8)n where n is the number of linked isoprene units. This is called the isoprene rule or the C5 rule. The isoprene units may be linked together "head to tail" to form linear chains or they may can be arranged to form rings. One can consider the isoprene unit as one of natures preferred building blocks.
lokundjoside
D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides
Desglucocheirotoxol
Convallatoxol is isolated from Convallaria majalis. Convallaria majalis is banned by the FDA from food use in the USA. Isolated from Convallaria majalis. Convallaria majalis is banned by the FDA from food use in the USA.
Lithocholate 3-O-glucuronide
Analysis of sequential bile samples by thin-layer chromatography (TLC) demonstrated that lithocholic acid glucuronide was present in bile throughout the course of the experiments and that its secretion rate paralleled that of total isotope secretion. Initial confirmation of the identity of this metabolite was obtained by the recovery of labeled lithocholic acid after beta-glucuronidase hydrolysis of bile samples. Glucuronates; Lithocholic Acid. Analysis of sequential bile samples by thin-layer chromatography (TLC) demonstrated that lithocholic acid glucuronide was present in bile throughout the course of the experiments and that its secretion rate paralleled that of total isotope secretion. Initial confirmation of the identity of this metabolite was obtained by the recovery of labeled lithocholic acid after beta-glucuronidase hydrolysis of bile samples. D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Arbekacin
Arbekacin is only found in individuals that have used or taken this drug. It is an semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA). Amikacin is also nephrotoxic and ototoxic.Aminoglycosides, such as Arbekacin, inhibit protein synthesis in susceptible bacteria by irreversibly binding to bacterial 30S and 16S ribosomal subunits. Specifically Arbekacin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic
D-Phenylalanyl-L-2-piperidinecarbonyl-N-(4-nitro phenyl)-L-argininamide
Lithocholic acid glucuronide
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
PA(2:0/PGF1alpha)
PA(2:0/PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGF1alpha), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(PGF1alpha/2:0)
PA(PGF1alpha/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF1alpha/2:0), in particular, consists of one chain of one Prostaglandin F1alpha at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Euhorbiasteroid
Euphorbiasteroid is a natural product found in Macaranga tanarius and Euphorbia lathyris with data available.
EFL1 diterpene
Bipindogulomethyloside
3-[(3R,5S,10R,13R,14S,17R)-5,14-dihydroxy-10,13-dimethyl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
3,9-epoxy-20alphaF-(2-ethyl-4-methyl-pyrrole-3-carbonyloxy)-25-methyl-(5beta)-14beta,13-[1]oxa[4]azapentano-18-nor-pregna-7,16-diene-3beta,11alpha-diol|Batrachotoxinin A-20-(2-ethyl-4-methyl-pyrrol-3-carboxylat) od. Homobatrachotoxin od. Isobatrachotoxin|homobatrachotoxin|O20-(2-ethyl-4-methyl-pyrrole-3-carbonyl)-batrachotoxinin-A
sarmentogenin-3-O-beta-D-allopyranoside|sarmentogenin-3beta-O-(beta-D-alloside)|sarmentogenin-3beta-O-
(19E,19E)-18,18-dideoxy-22,22-dinor-toxiferin-I|(19E,19E)-18,18-Didesoxy-22,22-dinor-toxiferin-I|Bisnordihydrotoxiferine|bisnordihydroxiferin|nordihydrotoxiferine
11-O-trans-Cinnamoyl-12-O-acetyl-17alphaH-marsdenin
(8E,12E,14E)-7-acetoxy-3,6,17,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide
(8E,12E,14E)-7-acetoxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide|(8E,12E,14E)-7-acetoxy-6,10,12,16,20-pentamethyl-3,6,16,21-tetrahydroxy-18,19-epoxytricosa-8,12,14-trien-11-olide|epi-(8E,12E,14E)-7-acetoxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19epoxytricosa-8,12,14-trien-11-olide
2-(beta-D-glucopyranosyloxy)-3,16-dihydroxy-4,4,9,14-tetramethyl-19-norpregn-5-en-20-one
16beta-hydroxy-heteroclitalactone H|heteroclitalactone I
(1S,2R,3S,4R,5R,6S,8E,11S,12R,13S,14S)-3-acetoxy-2,12-dibutanoyloxycladiell-8-ene-4,11-diol
3beta,27-dihydroxyolean-12-en-28-oic acid 3-sulfate ester
11-(2-Methylbutanoyl),12-benzoyl-Tenacigenin B|11alpha-O-2-methylbutyryl-12beta-O-benzoyltenacigenin B
2-O-pentadecanoyl-2-hydroxy-8-methoxy-6,7-methylenedioxyisoflavone|aervin D
3,4,5-trihydroxydrhydro-alpha-ionol-9-O-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranoside
2,3-DIACETOXY-7,8-EPOXY-24,29-DINOR-1,3,5-FRIEDELATRIENE-20-CARBOXYLIC ACID
C29H44O10_Card-20(22)-enolide, 3-(beta-D-glucopyranosyloxy)-5,14-dihydroxy-, (3alpha,5beta,8xi,9xi)
(2S,3S,4S,5R,6R)-6-(((3R,5R,8R,9S,10S,13R,14S,17R)-17-((R)-4-carboxybutan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
Arbekacin
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring. C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic
Cys Phe Lys Arg
Cys Phe Arg Lys
Cys Lys Phe Arg
Cys Lys Arg Phe
Cys Arg Phe Lys
Cys Arg Lys Phe
Asp Lys Lys Tyr
Asp Lys Tyr Lys
Asp Tyr Lys Lys
Phe Cys Lys Arg
Phe Cys Arg Lys
Phe His His Ile
Phe His His Leu
Phe His Ile His
Phe His Leu His
Phe Ile His His
Phe Lys Cys Arg
Phe Lys Lys Met
Phe Lys Met Lys
Phe Lys Met Gln
Phe Lys Gln Met
Phe Lys Arg Cys
Phe Leu His His
Phe Met Lys Lys
Phe Met Lys Gln
Phe Met Gln Lys
Phe Gln Lys Met
Phe Gln Met Lys
Phe Arg Cys Lys
Phe Arg Lys Cys
His Phe His Ile
His Phe His Leu
His Phe Ile His
His Phe Leu His
His His Phe Ile
His His Phe Leu
His His Ile Phe
His His Leu Phe
His Ile Phe His
His Ile His Phe
His Ile Gln Arg
His Ile Arg Gln
His Leu Phe His
His Leu His Phe
His Leu Gln Arg
His Leu Arg Gln
His Gln Ile Arg
His Gln Leu Arg
His Gln Arg Ile
His Gln Arg Leu
His Arg Ile Gln
His Arg Leu Gln
His Arg Gln Ile
His Arg Gln Leu
Ile Phe His His
Ile His Phe His
Ile His His Phe
Ile His Gln Arg
Ile His Arg Gln
Ile Gln His Arg
Ile Gln Arg His
Ile Arg His Gln
Ile Arg Gln His
Lys Cys Phe Arg
Lys Cys Arg Phe
Lys Asp Lys Tyr
Lys Asp Tyr Lys
Lys Phe Cys Arg
Lys Phe Lys Met
Lys Phe Met Lys
Lys Phe Met Gln
Lys Phe Gln Met
Lys Phe Arg Cys
Lys Lys Asp Tyr
Lys Lys Phe Met
Lys Lys Met Phe
Lys Lys Tyr Asp
Lys Met Phe Lys
Lys Met Phe Gln
Lys Met Lys Phe
Lys Met Gln Phe
Lys Gln Phe Met
Lys Gln Met Phe
Lys Arg Cys Phe
Lys Arg Phe Cys
Lys Arg Ser Tyr
Lys Arg Tyr Ser
Lys Ser Arg Tyr
Lys Ser Tyr Arg
Lys Tyr Asp Lys
Lys Tyr Lys Asp
Lys Tyr Arg Ser
Lys Tyr Ser Arg
Leu Phe His His
Leu His Phe His
Leu His His Phe
Leu His Gln Arg
Leu His Arg Gln
Leu Gln His Arg
Leu Gln Arg His
Leu Arg His Gln
Leu Arg Gln His
Met Phe Lys Lys
Met Phe Lys Gln
Met Phe Gln Lys
Met Lys Phe Lys
Met Lys Phe Gln
Met Lys Lys Phe
Met Lys Gln Phe
Met Gln Phe Lys
Met Gln Lys Phe
Gln Phe Lys Met
Gln Phe Met Lys
Gln His Ile Arg
Gln His Leu Arg
Gln His Arg Ile
Gln His Arg Leu
Gln Ile His Arg
Gln Ile Arg His
Gln Lys Phe Met
Gln Lys Met Phe
Gln Leu His Arg
Gln Leu Arg His
Gln Met Phe Lys
Gln Met Lys Phe
Gln Arg His Ile
Gln Arg His Leu
Gln Arg Ile His
Gln Arg Leu His
Arg Cys Phe Lys
Arg Cys Lys Phe
Arg Phe Cys Lys
Arg Phe Lys Cys
Arg His Ile Gln
Arg His Leu Gln
Arg His Gln Ile
Arg His Gln Leu
Arg Ile His Gln
Arg Ile Gln His
Arg Lys Cys Phe
Arg Lys Phe Cys
Arg Lys Ser Tyr
Arg Lys Tyr Ser
Arg Leu His Gln
Arg Leu Gln His
Arg Gln His Ile
Arg Gln His Leu
Arg Gln Ile His
Arg Gln Leu His
Arg Ser Lys Tyr
Arg Ser Tyr Lys
Arg Tyr Lys Ser
Arg Tyr Ser Lys
Ser Lys Arg Tyr
Ser Lys Tyr Arg
Ser Arg Lys Tyr
Ser Arg Tyr Lys
Ser Tyr Lys Arg
Ser Tyr Arg Lys
Tyr Asp Lys Lys
Tyr Lys Asp Lys
Tyr Lys Lys Asp
Tyr Lys Arg Ser
Tyr Lys Ser Arg
Tyr Arg Lys Ser
Tyr Arg Ser Lys
Tyr Ser Lys Arg
Tyr Ser Arg Lys
Deglucocheirotoxol
Cuspidoside
D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides
ST 24:1;O3;GlcA
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
2-(16-isoquinolin-2-ium-2-ylhexadecyl)isoquinolin-2-ium,dichloride
LEE011 succinate
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
14,15-Dihydroajugapitin
A diterpenoid isolated from the aerial parts of Ajuga bracteosa.
2-{bis[3-(dimethylamino)propyl]amino}-4-[(3-methyl-1,3-benzothiazol-2(3H)-ylidene)methyl]-1-phenylquinolinium
diaminomethylidene-[4-[[5-[(E)-3-[4-(diaminomethylideneazaniumyl)butylamino]-3-oxoprop-1-enyl]-2-(4-hydroxyphenyl)-2,3-dihydro-1-benzofuran-3-carbonyl]amino]butyl]azanium
3-[(21S,22S)-11-ethyl-4-hydroxy-16-[(1R)-1-hydroxyethyl]-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
Lithocholic acid glucuronide
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
15-hydroxyajubractin C
A diterpenoid isolated from the aerial parts of Ajuga bracteosa.
1-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-methoxyphenyl)urea
1-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-methoxyphenyl)urea
1-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-methoxyphenyl)urea
1-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-methoxyphenyl)urea
[1-acetyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-tridec-9-enoate
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-hexadec-9-enoate
[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-tetradec-9-enoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-octadec-9-enoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (Z)-heptadec-9-enoate
(1-butanoyloxy-3-phosphonooxypropan-2-yl) (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-hexadec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-heptadec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (Z)-tetradec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (Z)-tridec-9-enoate
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-octadec-9-enoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-pentadec-9-enoate
[1-[(E)-dec-4-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-phosphonooxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate
lithocholic acid 24-O-(beta-D-glucuronide)
A steroid glucosiduronic acid obtained by formal condensation of the carboxy group of lithodeoxycholic acid with the anomeric hydroxy group of beta-D-glucuronic acid.
lithocholic acid 3-O-(beta-D-glucuronide)
A steroid glucosiduronic acid that is lithocholic acid having a single beta-D-glucuronic acid residue attached at position 3.
(2'r,5r,6s,9's,9bs)-2',6-dihydroxy-2',6,9,11'-tetramethyl-6'-methylidene-2,7'-dioxo-4,5,6a,7,9a,9b-hexahydro-3ah-8'-oxaspiro[azuleno[4,5-b]furan-3,12'-tetracyclo[9.2.2.0¹,¹⁰.0⁵,⁹]pentadecan]-14'-en-5-yl acetate
4-(3a,5a-dihydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl)-5h-furan-2-one
(1r,2r)-1-(3,4-dimethoxyphenyl)-2-{4-[(2s,3r,4r,5s)-5-(3,4-dimethoxyphenyl)-3,4-dimethyloxolan-2-yl]-3-methoxyphenoxy}propan-1-ol
4-[(1r,3as,3bs,5ar,7s,9ar,9bs,10r,11ar)-3a,10-dihydroxy-9a-(hydroxymethyl)-11a-methyl-7-{[(2r,3r,4r,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one
(2e,4e,6r)-n-[(3r,4s)-3,4-dihydroxy-3-[(1e,3e,5e)-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl]-6-oxocyclohex-1-en-1-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid
(1'r,2r,3'e,5'r,7's,11's,12'r,13's,14's)-1',11'-bis(acetyloxy)-3',6',6',14'-tetramethyl-2'-oxospiro[oxirane-2,10'-tricyclo[10.3.0.0⁵,⁷]pentadecan]-3'-en-13'-yl 2-phenylacetate
5-(acetyloxy)-14-(butanoyloxy)-6,11-dihydroxy-3-isopropyl-6,10,14-trimethyl-15-oxatricyclo[6.6.1.0²,⁷]pentadec-9-en-4-yl butanoate
(4e,7s)-n-[(2z,4z)-2-(chloromethylidene)-4-methoxy-6-(4-methoxy-2-oxo-5h-pyrrol-1-yl)-6-oxohex-4-en-1-yl]-7-methoxy-n-methyltetradec-4-enamide
(2s,3r,4r,5r,6r)-2-methyl-6-{[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-{[(2r,3e)-4-[(1s,2s,4s)-1,2,4-trihydroxy-2,6,6-trimethylcyclohexyl]but-3-en-2-yl]oxy}oxan-2-yl]methoxy}oxane-3,4,5-triol
(1s,3r,5s,6s,15r,18e,21s,23s)-5,10-dihydroxy-6,12,17,17,21,27-hexamethyl-7,22,24,28-tetraoxahexacyclo[21.4.3.0¹,²³.0³,²¹.0⁶,¹⁵.0⁸,¹³]triaconta-8,10,12,18,26-pentaene-25,29-dione
(1r,2s,3r,4ar,5s,6r,8s,8ar)-5-[(2s,3ar,6as)-hexahydrofuro[2,3-b]furan-2-yl]-8-(acetyloxy)-8a-[(acetyloxy)methyl]-3-hydroxy-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-2-yl (2s)-2-methylbutanoate
4-[3a,11-dihydroxy-9a-(hydroxymethyl)-11a-methyl-7-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-tetradecahydrocyclopenta[a]phenanthren-1-yl]-5h-furan-2-one
(4ar,5r,6as,6br,8ar,12ar,12br,14bs)-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-(sulfooxy)-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid
4-[(1r,3as,3bs,5as,7r,9ar,9br,10r,11ar)-3a,5a,10-trihydroxy-9a,11a-dimethyl-7-{[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one
(1's,2s,2's,4'r,9's,11'e,15'r)-2',20'-dihydroxy-1',3,9',13',13',18'-hexamethyl-5-oxo-8',23'-dioxaspiro[furan-2,6'-tetracyclo[13.8.0.0⁴,⁹.0¹⁷,²²]tricosane]-11',17',19',21'-tetraen-7'-ylideneacetic acid
8-(acetyloxy)-8a-[(acetyloxy)methyl]-5-{hexahydrofuro[2,3-b]furan-2-yl}-2-hydroxy-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-4-yl 2-methylbutanoate
13-(chloromethyl)-2,3,9-trihydroxy-4,6a,11,11,14b-pentamethyl-2,3,4a,5,6,7,8,9,10,12,12a,13,14,14a-tetradecahydro-1h-picene-4,8a-dicarboxylic acid
2-{[5,7-dihydroxy-2,2-dimethyl-6-(2-methylpropanoyl)chromen-8-yl]methyl}-3,5-dihydroxy-4-methyl-4-(3-methylbut-2-en-1-yl)-6-(2-methylpropanoyl)cyclohexa-2,5-dien-1-one
18-(acetyloxy)-6-(furan-3-yl)-11-hydroxy-1,5,10,15-tetramethyl-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-16-yl 2-methylbut-2-enoate
2-(dimethylamino)-3-phenyl-n-[5,8,11-trihydroxy-3-isopropyl-7-(2-methylpropyl)-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,12,15-pentaen-4-yl]propanimidic acid
2-{7-[3-(2,3-dihydroxypentan-2-yl)oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl}-7,10-dihydroxy-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl acetate
4-{[5,7-dihydroxy-2,2-dimethyl-8-(2-methylpropanoyl)chromen-6-yl]methyl}-3,5-dihydroxy-6-methyl-6-(3-methylbut-2-en-1-yl)-2-(2-methylpropanoyl)cyclohexa-2,4-dien-1-one
(28e)-28,37-diethylidene-8,14,24,30-tetraazaundecacyclo[25.5.2.2¹¹,¹⁴.1¹,⁸.1¹⁰,¹⁷.0²,⁷.0¹³,¹⁷.0¹⁸,²³.0³⁰,³³.0²⁴,³⁵.0²⁶,³⁸]octatriaconta-2,4,6,9,18,20,22,25-octaene
(9r,13s,15s,16r,17r,18s)-15-hydroxy-16-[(1r)-1-hydroxy-1-[(2s)-5-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-8,8,13,17-tetramethyl-6-oxo-7-oxatetracyclo[10.7.0.0³,⁹.0¹³,¹⁷]nonadeca-1(12),2,4,10-tetraen-18-yl acetate
1-(3,4-dimethoxyphenyl)-2-{4-[5-(3,4-dimethoxyphenyl)-3,4-dimethyloxolan-2-yl]-2-methoxyphenoxy}propan-1-ol
19-hydroxy-sarmentogenin-3β-o-β-6-deoxygu-loside
{"Ingredient_id": "HBIN002200","Ingredient_name": "19-hydroxy-sarmentogenin-3\u03b2-o-\u03b2-6-deoxygu-loside","Alias": "NA","Ingredient_formula": "C29H44O10","Ingredient_Smile": "CC1C(C(C(C(O1)OC2CCC3(C(C2)CCC4C3C(CC5(C4(CCC5C6=CC(=O)OC6)O)C)O)CO)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10691","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
3β,5β,11α,14β-tetrahydroxy-5β-card-20(22)eno-lide-3α-l-rhamnoside
{"Ingredient_id": "HBIN008092","Ingredient_name": "3\u03b2,5\u03b2,11\u03b1,14\u03b2-tetrahydroxy-5\u03b2-card-20(22)eno-lide-3\u03b1-l-rhamnoside","Alias": "3beta,5beta,11alpha,14beta-tetrahydroxy-5beta-card-20(22)enolide-3alpha-l-rhamnoside","Ingredient_formula": "C29H44O10","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21068;32028","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
alliside
{"Ingredient_id": "HBIN015203","Ingredient_name": "alliside","Alias": "NA","Ingredient_formula": "C29H44O10","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "922","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
antiogoside
{"Ingredient_id": "HBIN016377","Ingredient_name": "antiogoside","Alias": "NA","Ingredient_formula": "C29H44O10","Ingredient_Smile": "CC1C(C(C(C(O1)OC2CCC3(C4CC(C5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)O)C)O)O)O","Ingredient_weight": "552.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "6739;21613","PubChem_id": "21550487","DrugBank_id": "NA"}